GH Peptides and IGF-1: What to Monitor

Running a GH secretagogue protocol without monitoring bloodwork is like driving without a speedometer—you have no idea whether you're in the effective range, wasting material, or pushing into territory that could cause problems. IGF-1 (Insulin-like Growth Factor 1) is the primary biomarker researchers use to assess GH peptide response, but it is far from the only thing worth tracking. The relationship between GH secretagogue administration, circulating GH levels, and downstream IGF-1 production is more nuanced than most online discussions suggest, and understanding these dynamics is essential for any rigorous research protocol.

This guide covers everything researchers need to know about monitoring the GH/IGF-1 axis during peptide use: what to test, when to test, how to interpret results, what confounding variables to account for, and which safety markers deserve attention beyond IGF-1 itself.

Why IGF-1 Is the Primary Marker

Growth hormone itself is a poor biomarker for monitoring GH peptide response, and understanding why is fundamental to proper monitoring. GH is secreted in pulsatile bursts—levels can spike 10-fold or more during a pulse and return to near-undetectable levels within 60–90 minutes. A random GH blood draw tells you almost nothing useful because the result depends entirely on whether you happened to catch a pulse or a trough. The only reliable way to measure total GH output is frequent sampling over 12–24 hours (every 10–20 minutes), which is impractical outside of a research hospital setting.

IGF-1 solves this problem. Produced primarily in the liver in response to GH stimulation, IGF-1 has a half-life of approximately 12–16 hours and circulates bound to binding proteins (primarily IGFBP-3) that further stabilize its levels. The result is that serum IGF-1 reflects integrated GH exposure over days to weeks, not moment-to-moment fluctuations. A single morning blood draw captures a meaningful, reproducible snapshot of the GH axis’s functional output.

However, IGF-1 is not a perfect proxy for GH activity. Several factors modulate the GH-to-IGF-1 conversion, including nutritional status (protein and caloric intake), liver function, thyroid status, insulin levels, sex hormone status (estrogen in particular), and age. Two individuals on identical GH peptide protocols can produce meaningfully different IGF-1 responses based on these variables alone. This is why interpreting IGF-1 requires context, not just a number.

Baseline Bloodwork: What to Test Before Starting

A proper baseline is the foundation of meaningful monitoring. Without pre-protocol values, you cannot assess change, identify pre-existing conditions that might affect response, or detect adverse trends once the protocol begins. The following panel represents what informed researchers consider the minimum for a GH peptide research protocol.

Core GH Axis Markers

IGF-1: This is the anchor of the monitoring panel. Baseline IGF-1 establishes where the subject starts and defines the range within which dose titration will occur. Age- and sex-matched reference ranges are essential for interpretation—a 25-year-old male at 280 ng/mL is in a very different physiological context than a 55-year-old female at the same number.

IGFBP-3 (IGF Binding Protein 3): The major carrier protein for IGF-1 in circulation. IGFBP-3 is GH-dependent and provides additional confirmation of GH axis status. Some researchers find the IGF-1:IGFBP-3 ratio more informative than IGF-1 alone, as it better approximates "free" (bioactive) IGF-1 levels. IGFBP-3 also has independent diagnostic value—discordance between IGF-1 and IGFBP-3 can suggest hepatic dysfunction or nutritional factors confounding the IGF-1 reading.

Metabolic Markers

Fasting glucose and fasting insulin: GH is a counter-regulatory hormone to insulin, meaning it promotes insulin resistance. Any protocol that elevates GH should include monitoring of glucose homeostasis. Fasting glucose alone is insufficient—it can remain normal while insulin levels climb to compensate, masking developing insulin resistance. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), calculated from fasting glucose and fasting insulin, provides a more sensitive early indicator.

HbA1c: While less sensitive to short-term changes than fasting glucose/insulin, HbA1c reflects average glucose over 2–3 months and catches trends that fasting measures might miss between testing intervals.

Thyroid Function

TSH, Free T4, Free T3: GH increases the conversion of T4 to T3 (the more active thyroid hormone) via stimulation of peripheral deiodinase enzymes. This can create a pattern where Free T3 rises while Free T4 drops, potentially lowering TSH through feedback. In subjects with borderline or subclinical thyroid issues, GH peptide use can unmask or exacerbate hypothyroidism. Baseline thyroid function provides the reference point needed to detect these shifts.

Additional Markers

Prolactin: Relevant primarily for GHRP-class peptides (GHRP-2, GHRP-6) and MK-677, which can elevate prolactin. Less critical for Ipamorelin or GHRH analogs, but a baseline value is still useful.

Comprehensive Metabolic Panel (CMP): Liver function (ALT, AST), kidney function (creatinine, BUN), and electrolytes provide a safety baseline and can reveal conditions that might affect IGF-1 production or peptide metabolism.

Fasting lipid panel: GH influences lipid metabolism—it tends to promote lipolysis and can alter LDL/HDL ratios over time. A baseline allows tracking of these changes.

IGF-1 Reference Ranges and Target Levels

One of the most common questions in GH peptide research is "what IGF-1 level should I be aiming for?" The answer is more nuanced than a single number, because IGF-1 reference ranges vary significantly by age, sex, and assay methodology.

Standard laboratory reference ranges for IGF-1 are established from population data and represent approximately the 2.5th to 97.5th percentile for a given age and sex group. These ranges decline substantially with age. A 25-year-old male might have a reference range of 115–358 ng/mL, while a 60-year-old male’s range might be 64–210 ng/mL. Women generally have similar or slightly lower ranges than age-matched men, though the sex difference is less dramatic than many expect.

The most common research target described in community protocols is the upper quartile of the age- and sex-appropriate reference range. The rationale is that this level corresponds to what a well-functioning, youthful GH axis would produce naturally—optimized but not supraphysiological. Researchers generally avoid pushing IGF-1 above the reference range upper limit, as epidemiological data (discussed below) associates chronically elevated IGF-1 with increased disease risk.